Sign in or Register   Sign in or Register
  |  

Mouse Anti-LILRB1 Recombinant Antibody (4F9) (CBMAB-C2081-LY)

This product is antibody recognizes LILRB1. The antibody 4F9 immunoassay techniques such as: IHC-F, FC.
See all LILRB1 antibodies

Summary

Host Animal
Mouse
Specificity
Human
Clone
4F9
Antibody Isotype
IgG1
Application
IHC-F, FC

Basic Information

Immunogen
Monocyte derived dendritic cells
Specificity
Human
Antibody Isotype
IgG1
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Concentration
1 mg/ml
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freezethaw cycles.

Target

Full Name
LILRB1
Entrez Gene ID
10859
UniProt ID
Q8NHL6
Function
Receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C, HLA-G and HLA-F alleles (PubMed:16455647, PubMed:28636952).
Receptor for H301/UL18, a human cytomegalovirus class I MHC homolog. Ligand binding results in inhibitory signals and down-regulation of the immune response. Engagement of LILRB1 present on natural killer cells or T-cells by class I MHC molecules protects the target cells from lysis. Interaction with HLA-B or HLA-E leads to inhibition of FCER1A signaling and serotonin release. Inhibits FCGR1A-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions (PubMed:11907092, PubMed:9285411, PubMed:9842885).
Recognizes HLA-G in complex with B2M/beta-2 microglobulin and a nonamer self-peptide (PubMed:16455647).
Upon interaction with peptide-bound HLA-G-B2M complex, triggers secretion of growth-promoting factors by decidual NK cells (PubMed:29262349, PubMed:19304799).
Reprograms B cells toward an immune suppressive phenotype (PubMed:24453251).
Biological Process
Adaptive immune responseIEA:UniProtKB-KW
Cellular response to lipopolysaccharideManual Assertion Based On ExperimentIEP:UniProtKB
Cytokine-mediated signaling pathwayManual Assertion Based On ExperimentIBA:GO_Central
Defense response to virusManual Assertion Based On ExperimentIDA:UniProtKB
Dendritic cell differentiationManual Assertion Based On ExperimentIEP:UniProtKB
Fc receptor mediated inhibitory signaling pathwayManual Assertion Based On ExperimentIDA:UniProtKB
Immune response-inhibiting cell surface receptor signaling pathway1 PublicationNAS:BHF-UCL
Negative regulation of alpha-beta T cell activationManual Assertion Based On ExperimentIDA:UniProtKB
Negative regulation of calcium ion transportManual Assertion Based On ExperimentIDA:UniProtKB
Negative regulation of CD8-positive, alpha-beta T cell activationManual Assertion Based On ExperimentIDA:UniProtKB
Negative regulation of cell cycleManual Assertion Based On ExperimentIDA:UniProtKB
Negative regulation of cytokine production involved in immune responseManual Assertion Based On ExperimentIDA:UniProtKB
Negative regulation of dendritic cell apoptotic processManual Assertion Based On ExperimentIDA:UniProtKB
Negative regulation of dendritic cell differentiationManual Assertion Based On ExperimentIMP:UniProtKB
Negative regulation of endocytosisManual Assertion Based On ExperimentIDA:UniProtKB
Negative regulation of interferon-beta productionManual Assertion Based On ExperimentIDA:UniProtKB
Negative regulation of interferon-gamma productionManual Assertion Based On ExperimentIDA:UniProtKB
Negative regulation of interleukin-10 productionManual Assertion Based On ExperimentIDA:UniProtKB
Negative regulation of interleukin-12 productionManual Assertion Based On ExperimentIDA:UniProtKB
Negative regulation of mononuclear cell proliferationManual Assertion Based On ExperimentIDA:UniProtKB
Negative regulation of natural killer cell mediated cytotoxicityManual Assertion Based On ExperimentIDA:UniProtKB
Negative regulation of osteoclast developmentManual Assertion Based On ExperimentIDA:UniProtKB
Negative regulation of serotonin secretionManual Assertion Based On ExperimentIDA:UniProtKB
Negative regulation of T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cellManual Assertion Based On ExperimentIDA:UniProtKB
Negative regulation of T cell mediated cytotoxicityManual Assertion Based On ExperimentIDA:UniProtKB
Negative regulation of T cell proliferationManual Assertion Based On ExperimentIDA:UniProtKB
Negative regulation of transforming growth factor beta productionManual Assertion Based On ExperimentIDA:UniProtKB
Negative regulation of tumor necrosis factor productionManual Assertion Based On ExperimentIDA:UniProtKB
Positive regulation of apoptotic processManual Assertion Based On ExperimentIDA:UniProtKB
Positive regulation of defense response to virus by hostManual Assertion Based On ExperimentIDA:UniProtKB
Positive regulation of gamma-delta T cell activation involved in immune responseManual Assertion Based On ExperimentIDA:UniProtKB
Positive regulation of gene expressionManual Assertion Based On ExperimentIDA:UniProtKB
Positive regulation of interferon-gamma productionManual Assertion Based On ExperimentIDA:UniProtKB
Positive regulation of macrophage cytokine productionManual Assertion Based On ExperimentIDA:UniProtKB
Positive regulation of transcription by RNA polymerase II1 PublicationNAS:BHF-UCL
Receptor internalizationManual Assertion Based On ExperimentTAS:UniProtKB
Response to virusManual Assertion Based On ExperimentIDA:UniProtKB
Signal transductionManual Assertion Based On ExperimentIDA:UniProtKB
T cell proliferation involved in immune responseManual Assertion Based On ExperimentIDA:UniProtKB
Cellular Location
Cell membrane
Isoform 5:
Secreted
Topology
Extracellular: 24-461
Helical: 462-482
Cytoplasmic: 483-650
PTM
Phosphorylated on tyrosine residues. Dephosphorylated by PTPN6.

Zeller, T., Münnich, I. A., Windisch, R., Hilger, P., Schewe, D. M., Humpe, A., & Kellner, C. (2023). Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancer. Frontiers in Immunology, 14.

Zou, R., Zhong, X., Liang, K., Zhi, C., Chen, D., Xu, Z., ... & Wang, Y. (2023). Elevated LILRB1 expression predicts poor prognosis and is associated with tumor immune infiltration in patients with glioma. BMC cancer, 23(1), 1-21.

Churchill, H. R., Fuda, F. S., Xu, J., Deng, M., Zhang, C. C., An, Z., ... & Chen, W. (2021). Leukocyte immunoglobulin‐like receptor B1 and B4 (LILRB1 and LILRB4): Highly sensitive and specific markers of acute myeloid leukemia with monocytic differentiation. Cytometry Part B: Clinical Cytometry, 100(4), 476-487.

Wang, Q., Song, H., Cheng, H., Qi, J., Nam, G., Tan, S., ... & Gao, G. F. (2020). Structures of the four Ig-like domain LILRB2 and the four-domain LILRB1 and HLA-G1 complex. Cellular & Molecular Immunology, 17(9), 966-975.

Chen, H., Chen, Y., Deng, M., John, S., Gui, X., Kansagra, A., ... & Zhang, C. C. (2020). Antagonistic anti-LILRB1 monoclonal antibody regulates antitumor functions of natural killer cells. Journal for ImmunoTherapy of Cancer, 8(2).

Harrison, T. E., Mørch, A. M., Felce, J. H., Sakoguchi, A., Reid, A. J., Arase, H., ... & Higgins, M. K. (2020). Structural basis for RIFIN-mediated activation of LILRB1 in malaria. Nature, 587(7833), 309-312.

Zhao, J., Zhong, S., Niu, X., Jiang, J., Zhang, R., & Li, Q. (2019). The MHC class I‐LILRB1 signalling axis as a promising target in cancer therapy. Scandinavian journal of immunology, 90(5), e12804.

Kim, A., Han, C. J., Driver, I., Olow, A., Sewell, A. K., Zhang, Z., ... & Yu, X. (2019). LILRB1 blockade enhances bispecific T cell engager antibody–induced tumor cell killing by effector CD8+ T cells. The Journal of Immunology, 203(4), 1076-1087.

Barkal, A. A., Weiskopf, K., Kao, K. S., Gordon, S. R., Rosental, B., Yiu, Y. Y., ... & Maute, R. L. (2018). Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. Nature immunology, 19(1), 76-84.

Yu, K., Davidson, C. L., Wójtowicz, A., Lisboa, L., Wang, T., Airo, A. M., ... & Burshtyn, D. N. (2018). LILRB1 polymorphisms influence posttransplant HCMV susceptibility and ligand interactions. The Journal of clinical investigation, 128(4), 1523-1537.

Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-LILRB1 Recombinant Antibody (4F9)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare